STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197

Summary

Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Crm197 (CHEMBL6068493) is an approved vaccine component; indicated across 2 conditions including pneumococcal infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 60

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068493
Name	STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197
Type	Vaccine component
Max phase	4

Also known as: Prevenar, Prevenar 13, Prevenar 20 (previously apexxnar), Vaxneuvance

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumococcal infection	4	MONDO:0005114	EFO:0000772

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 60.

Phase distribution

Phase	Trials
PHASE3	34
PHASE4	9
PHASE2	9
Not specified	7
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04460235	PHASE4	RECRUITING	Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
NCT00276107	PHASE4	COMPLETED	Study Evaluating Prevenar Vaccine in Healthy Infants
NCT00294294	PHASE4	COMPLETED	Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa
NCT00581035	PHASE4	COMPLETED	Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
NCT00828997	PHASE4	COMPLETED	Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®
NCT00836641	PHASE4	COMPLETED	Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
NCT01193582	PHASE4	COMPLETED	A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
NCT01947010	PHASE4	COMPLETED	Pneumococcal Vaccination of Crohn Patients
NCT03565159	PHASE4	COMPLETED	Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors
NCT05759520	PHASE3	ACTIVE_NOT_RECRUITING	Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
NCT06693895	PHASE3	RECRUITING	A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
NCT06740630	PHASE3	RECRUITING	A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06806137	PHASE3	RECRUITING	A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
NCT06855160	PHASE3	RECRUITING	A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06975878	PHASE3	ACTIVE_NOT_RECRUITING	Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT07160244	PHASE3	RECRUITING	BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07593924	PHASE3	NOT_YET_RECRUITING	Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
NCT00169728	PHASE3	COMPLETED	Vaccination of Children Following Allogeneic Stem Cell Transplantation
NCT00344318	PHASE3	COMPLETED	Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals’ 10-valent Pneumococcal Conjugate Vaccine
NCT00370396	PHASE3	COMPLETED	Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine.
NCT00463437	PHASE3	COMPLETED	Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
NCT00547248	PHASE3	COMPLETED	Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
NCT00624819	PHASE3	COMPLETED	Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
NCT00657709	PHASE3	COMPLETED	Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00680914	PHASE3	COMPLETED	Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™
NCT00999739	PHASE3	UNKNOWN	Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
NCT01341639	PHASE3	COMPLETED	Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
NCT01432158	PHASE3	COMPLETED	Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines
NCT01439360	PHASE3	COMPLETED	An Efficacy Study of GlaxoSmithKline (GSK) Biologicals’ Candidate Influenza Vaccine GSK2321138A in Children
NCT01480258	PHASE3	COMPLETED	Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
NCT01619462	PHASE3	UNKNOWN	Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
NCT01641133	PHASE3	COMPLETED	Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
NCT01839175	PHASE3	COMPLETED	Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
NCT01839188	PHASE3	COMPLETED	Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
NCT01892618	PHASE3	COMPLETED	Pneumococcal Vaccine in Untreated CLL Patients
NCT01939158	PHASE3	COMPLETED	Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer’s Prevenar 13™Vaccine
NCT01942174	PHASE3	COMPLETED	VACcination In Methotrexate Treated Rheumatoid Arthritis Patients
NCT01983540	PHASE3	COMPLETED	Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
NCT02640703	PHASE3	COMPLETED	Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial
NCT03207750	PHASE3	COMPLETED	This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals’ Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK’s Licensed Lyophilized Vaccine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).